Cabiralizumab Uses, Dosage, Side Effects and more
Cabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).
| Trade Name | Cabiralizumab |
| Generic | Cabiralizumab |
| Cabiralizumab Other Names | Cabiralizumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
